CClinicalTrials.gg
CompletedNCT06034782Updated Sep 13, 2023

Diagnostic Accuracy of Fine Needle Aspiration in Patients With Salivary Gland Tumors.

An observational study in Salivary Gland Tumor and Diagnosis, sponsored by Aristotle University Of Thessaloniki. Completed at 1 site in Greece. Open to participants aged 24 Years to 96 Years. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Aristotle University Of Thessaloniki · Observational

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
128
Ages
24 Years to 96 Years
Sex
All
01

Study summary

Tumors of the salivary glands occupy 0.5-1.2% of cases of head and neck tumors. They are primarily a surgical disease, as their treatment is basically the surgical excision. In this direction and in the context of the differential preoperative diagnosis, in addition to the imaging methods, the fine needle biopsy (FNA) was used, with which cell material is aspirated from the tumor and studied under the microscope. Although an increasing number of papers have been published in the international scientific literature over the last 5 years on the diagnostic accuracy of FNA in salivary glands, many of them are unable to quantify and omit to refer information that could affect the estimated diagnostic accuracy. Such information is for instance the clinical experience of the doctor who performs the FNA and of the one who assess the smear. The aim of this retrospective study is to evaluate the diagnostic accuracy of fine needle biopsy in adult patients with salivary gland tumor that underwent a surgical excision in two Oral and Maxillofacial Departments in Northern Greece.

The present retrospective study was carried out from 2/2021 to 4/2022 by collecting data from the files of patients who underwent surgery at the Oral and Maxillofacial Clinic of the Theageneio Cancer Hospital of Thessaloniki 1996-2022 and the General Hospital of Thessaloniki G. Papanikolaou 2015-2022. The study was conducted according to the STARD 2015 protocol.

FNA contributed significantly to the differential preoperative process in salivary gland diseases. The differential diagnosis of a lesion in benign / malignant preoperatively, with the use of FNA, enables the surgeon for a more beneficial to the patient and oncologically safer planning of the surgery. It is considered important the high sensitivity provided by the examination, as it helps to exclude with sufficient safety the possible malignancy of the tumor located in the salivary gland of the patient.

Read the detailed description

This retrospective study was conducted according to the STARD 2015 protocol. A thorough retrospective analysis of patient data that were extracted from patient records of a tertiary referral hospital database was performed. The patient files which were included in the study are electronically archived at the Departments of Oral and Maxillofacial Surgery of "Theageneio Anti-Cancer Hospital of Thessaloniki" and of General Hospital of Thessaloniki "George Papanikolaou".

Patients who were included in the present study, except for clinical examination by an Oral and Maxillofacial Surgeon, also underwent at least one imaging modality (MRI, CT scan, ultrasound scan).

This retrospective study was carried out from 2/2021 to 4/2022. Data from records of patients who underwent salivary tumour surgery at the Oral and Maxillofacial Surgery departments of Theageneio Anti-Cancer Hospital of Thessaloniki 1996-2022 and of the General Hospital of Thessaloniki G. Papanikolaou 2015-2022 were collected.

The surgical treatment of all patients with salivary gland tumors who were examined by a practitioner of the two aforementioned Maxillofacial departments, was based on their chronological attendance at the outpatient clinic, while there was no attempt of grouping of them.

Based on the FNA report, FNA results were categorized as follows: Benign, Malignant, Non-diagnostic, Unavailable result. The same categories were obtained for the reference standard test, which was the histopathological examination of the resected tumor.

The sample size was calculated using the software G power analysis version 3.1.9.6. For α = 0.05 and study strength Power 0.95 a sample size of 102 patients had been obtained which was relatively smaller compared to the 128 patients that were finally included in the study.

During the data collection from the medical patient records, there were 11 (n = 11) out of 139 (n = 139) cases whose FNA result and 4 (n=4) out of 184 (n=184) whose histological result was non-diagnostic as it was not clearly concluded whether the lesion was benign or malignant. These cases were excluded from the estimation of diagnostic accuracy indicators. Likewise to the non-diagnostic results, were excluded the 145 (n = 145) FNA results that were not available.

To assess the diagnostic accuracy of FNA, a comparative process among FNA and histopathological outcomes was conducted. Sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, negative likelihood ratio, ROC curve and AUC (Area Under curve) were calculated. Calculations were made using software RStudio Version 1.4.1106 © 2009-2021 RStudio, PBC "Tiger Daylily" (2389bc24, 2021-02-11) for Windows Mozilla/5.0 (Windows NT 10.0; Win64; x64) Apple Web Kit/537.36 (KHTML, like Gecko) Qt Web Engine/5.12.8 Chrome/69.0.3497.128 Safari/537.36.

02

Conditions studied

  • Salivary Gland Tumor
  • Diagnosis

Keywords

  • salivary tumors
  • diagnostic accuracy
  • Fine Needle Aspiration
03

In context

Salivary Gland Neoplasms

156 studies on the registry are indexed under Salivary Gland Neoplasms; 29 are open to participants now.

This study's enrollment of 128 is below the median of 168 across 20 observational studies indexed under Salivary Gland Neoplasms.

Browse Salivary Gland Neoplasms studies →

Lead sponsor

Aristotle University Of Thessaloniki is the lead sponsor of 274 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
24 Years to 96 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients with salivary tumors that examined in outpatient Oral and Maxillofacial Surgery Clinic of Anti-Cancer Hospital of Thessaloniki "Theageneio" and General Hospital of Thessaloniki "G. Papanikolaou".

Inclusion criteria

  • Adult patients >=18 years
  • salivary tumor suspected
  • FNA result available
  • Salivary tumor surgically resected
  • Histologic result available

Exclusion criteria

Exclusion Criteria:

  • Patients under 18 years old
  • FNA result or Histologic result not available
  • No tumor resection
  • Other neck tumors (not salivary tumor)
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
128 participants (actual)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • patients with salivary gland tumors

    patients with salivary gland tumors

    Diagnostic Test: Fine Needle Aspiration · Procedure: Histologic Examination

Interventions

  • Diagnostic testFine Needle Aspiration

    Fine Needle Aspiration of a salivary gland tumor

    Also known as: FNA

  • ProcedureHistologic Examination

    Histologic examination of resected salivary tumor

06

What researchers measure

Primary outcomes

  1. Diagnostic accuracy of Fine Needle Aspiration in salivary tumors

    The result FNA of salivary tumor was compared to (verified) Histologic result after tumor resection. Then Diagnostic accuracy of FNA was estimated.

    Time frame: Every patient underwent FNA in a time frame from 1 day to 1 month before the surgical resection of the tumor. Then, under general anesthesia the tumor was surgicaly resected and was immediately examined to the Histology Laboratory of the Hospital.

07

Study locations

1 site
  • Aristotle University
    Thessaloníki, 54124, Greece
08

References and documents

Individual participant data

Plan to share: Yes — SN,Sex,Clinic of Origin,Date of Birth,Age, Final Result of FNA (as included in Excel database),Histological result (as included in Excel database) are available to all researchers.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06034782
Lead sponsor
Aristotle University Of Thessaloniki
Responsible party
Sponsor
First posted
Sep 13, 2023
Start date
Feb 22, 2021
Primary completion
May 15, 2022
Completion
Jun 6, 2022
Last update
Sep 13, 2023

Study contacts

Theodoros V. Grivas, Medical
principal investigator · Aristotle University Thessaloniki

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion